Clinical trial NCT00236080: Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL® (200 mg) in Patients With Chronic Shift Work Sleep Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Shift Work Sleep Disorder
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2005-10-12
Enrollment: 136
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).

Detailed description: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL in Patients with Chronic Shift Work Sleep Disorder

Eligibility criteria: Inclusion Criteria:

Patients are included in the study if all of the following criteria are met:

* The patient speaks and writes in English.
* The patient is a man or woman of any ethnic origin aged 18 through 65 years.
* The patient is in good health as determined by a medical and psychiatric history, medical examination, serum chemistry, and hematology.
* The patient has a diagnosis of SWSD according to the International Classification of Sleep Disorders (ICSD) criteria, and must have had excessive sleepiness during night shifts for at least 3 months.
* The patient must be planning to work at least 3 to 5 nights (per week), of which at least 3 nights will be consecutive.
* The patient must work night shifts that include at least 6 hours between 2200 and 0800 (+30 minutes) and be no longer than 12 hours (+30 minutes) in duration.
* The patient has a mean sleep latency of 6 minutes or less as determined by the MSLT (average of naps at 0100, 0300, 0500, and 0700).
* The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more as it pertains to sleepiness during night shifts including the commute from work.
* Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted and injected) in conjunction with a barrier method, and intrauterine device (IUD).
* The patient is willing to comply with study restrictions and remain at the clinic overnight as required.
* The patient may have been prescribed PROVIGIL or stimulant therapy for their sleep disorder; however, they must have undergone a washout period of at least 7 days prior to screening assessments done at the second screening visit.

Exclusion Criteria:

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

* The patient has any clinically significant medical or psychiatric conditions (treated or untreated).
* The patient has a probable diagnosis of a current sleep disorder other than SWSD.
* The patient consumes caffeine including coffee, tea, and/or other caffeine-containing beverages or foods averaging more than 600 mg of caffeine/day within 2 weeks of the start of study drug administration.
* The patient has medically unexplainable positive urine drug screen (UDS) result at the screening visit.
* The patient has clinically significant deviation from normal in clinical laboratory results, vital signs, or physical examination.
* The patient has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before study drug administration, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before study drug adminstration.
* The patient used any prescription drugs disallowed by the protocol or clinical significant use of over-the-counter (OTC) drugs within 7 days before the second screening/baseline visit.
* The patient has any disorder (including gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
* The patient has known or suspected hypersensitivity to stimulants and/or modafinil or any ingredient present in the study drug.
* The patient has a history (within the past 5 years) of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual or Mental Disorders of the American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR).
* The patient is a pregnant or lactating woman.
* The patient has donated, within 56 days prior to study drug administration, any blood or plasma in excess of 450 mL.

Primary outcomes:
measure: Multiple Sleep Latency Test (MSLT)
timeFrame: Endpoint (Visit 4) change from baseline (Visit 2)
measure: Psychomotor Vigilance Task (PVT)
timeFrame: Endpoint (Visit 4) change from baseline (Visit 2)
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Psypharma Clinical Research
state: Arizona
city: Tucson
country: United States
facility: PsyPharma Clinical Tucson
state: Arizona
city: Hot Springs
country: United States
facility: Central Arkansas Research
state: Arkansas
city: Los Angeles
country: United States
facility: Pacific Sleep Medicine Service
state: California
city: San Diego
country: United States
facility: Pacific Sleep Medicine Service
state: California
city: San Diego
country: United States
facility: BMR HealthQuest
state: California
city: Stanford
country: United States
facility: Stanford University
state: California
city: Atlanta
country: United States
facility: Neurotrials Research
state: Georgia
city: Macon
country: United States
facility: SLEEPMED, Inc.
state: Georgia
city: Northfield
country: United States
facility: Henry Lahmeyer, MD
state: Illinois
city: Overland Park
country: United States
facility: Vince and Associates Clinical
state: Kansas
city: Chevy Chase
country: United States
facility: Center for Sleep/Wake Disorder
state: Maryland
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
city: Las Vegas
country: United States
facility: Clinical Rsch Center of Nevada
state: Nevada
city: New York
country: United States
facility: Clinilabs / Sleep Disorders In
state: New York
city: Raleigh
country: United States
facility: Wake Research Associates
state: North Carolina
city: Toledo
country: United States
facility: St. Vincent Mercy Medical Cent
state: Ohio
city: Pittsburgh
country: United States
facility: Consolidated Clinical Trials
state: Pennsylvania
city: Columbia
country: United States
facility: SleepMed of South Carolina
state: South Carolina
city: Salt Lake City
country: United States
facility: Radiant Research Salt Lake
state: Utah
Study officials:
affiliation: Cephalon
name: Gwendolyn Neibler, DO
role: STUDY_DIRECTOR
References: